Ranibizumab (Ascendis Pharma)

雷珠单抗 (Ascendis Pharma)

Report date: 2024/06/17 16:33:50

Base Information

Drug NameRanibizumab (Ascendis Pharma)

Drug Alias NameTransCon-RBZTransCon RBZ

ClassificationBiologics > Protein drugs > Immunoglobulin > Antibody > Monoclonal antibody > Monoclonal antibody humanizedBiologics > Protein drugs > Immunoglobulin > Antibody > Antibody fragment > Fab fragment

Mechanisms of ActionVascular endothelial growth factor A inhibitors

TargetsVascular endothelial growth factor A

Therapy Area/IndicationsWet age-related macular degeneration

Global Approved IndicationsN/A

Approved Indications in ChinaN/A

Original Approved Country/TerritoryN/A

Original Approved DateN/A

Country/TerritoryDenmark

CombinationsNo

Global Highest StatusPreclinical

Highest Status in ChinaN/A

Originator CompaniesAscendis Pharma A/S

China Registration ClassN/A

Develop Information

Active CompaniesAscendis Pharma A/S

Inactive CompaniesN/A

Active IndicationsWet age-related macular degeneration

Inactive IndicationsN/A

Other Information

ATC CodeN/A